The therapeutic use of siRNA against CEACAM6 in pancreatic adenocarcinoma was studied by Duxbury et al. 42CEACAM6 gene silencing resulted in tumour regression in a pancreatic adenocarcinoma xenograft model, including diminished tumour proliferation and improved survival. Here, CEACAM6 is linked to neoplasm.